[en] Background: Treatment of acute respiratory distress syndrome (ARDS) associated with COronaVIrus Disease-2019 (COVID-19) currently relies on dexamethasone and supportive mechanical ventilation, and remains associated with high mortality. Given their ability to limit inflammation, induce immune cells into a regulatory phenotype and stimulate tissue repair, mesenchymal stromal cells (MSCs) represent a promising therapy for severe and critical COVID-19 disease, which is associated with an uncontrolled immune-mediated inflammatory response. Methods: In this phase I-II trial, we aimed to evaluate the safety and efficacy of 3 intravenous infusions of bone marrow (BM)-derived MSCs at 3-day intervals in patients with severe COVID-19. All patients also received dexamethasone and standard supportive therapy. Between June 2020 and September 2021, 8 intensive care unit patients requiring supplemental oxygen (high-flow nasal oxygen in 7 patients, invasive mechanical ventilation in 1 patient) were treated with BM-MSCs. We retrospectively compared the outcomes of these MSC-treated patients with those of 24 matched control patients. Groups were compared by paired statistical tests. Results: MSC infusions were well tolerated, and no adverse effect related to MSC infusions were reported (one patient had an ischemic stroke related to aortic endocarditis). Overall, 3 patients required invasive mechanical ventilation, including one who required extracorporeal membrane oxygenation, but all patients ultimately had a favorable outcome. Survival was significantly higher in the MSC group, both at 28 and 60 days (100% vs 79.2%, p = 0.025 and 100% vs 70.8%, p = 0.0082, respectively), while no significant difference was observed in the need for mechanical ventilation nor in the number of invasive ventilation-free days, high flow nasal oxygenation-free days, oxygen support-free days and ICU-free days. MSC-treated patients also had a significantly lower day-7 D-dimer value compared to control patients (median 821.0 µg/L [IQR 362.0-1305.0] vs 3553 µg/L [IQR 1155.0-6433.5], p = 0.0085). Conclusions: BM-MSC therapy is safe and shows very promising efficacy in severe COVID-19, with a higher survival in our MSC cohort compared to matched control patients. These observations need to be confirmed in a randomized controlled trial designed to demonstrate the efficacy of BM-MSCs in COVID-19 ARDS. Clinical Trial Registration (www.ClinicalTrials.gov), identifier NCT04445454
Disciplines :
Anesthesia & intensive care Immunology & infectious disease Cardiovascular & respiratory systems
Author, co-author :
GREGOIRE, Céline ✱; Centre Hospitalier Universitaire de Liège - CHU > > Service d'hématologie clinique
LAYIOS, Nathalie ✱; Centre Hospitalier Universitaire de Liège - CHU > > Service des soins intensifs
LAMBERMONT, Bernard ; Centre Hospitalier Universitaire de Liège - CHU > > Service des soins intensifs
LECHANTEUR, Chantal ; Centre Hospitalier Universitaire de Liège - CHU > > Thérapie cellulaire
BRIQUET, Alexandra ; Centre Hospitalier Universitaire de Liège - CHU > > Thérapie cellulaire
Bettonville, Virginie ; Centre Hospitalier Universitaire de Liège - CHU > > Thérapie cellulaire
BAUDOUX, Etienne ; Centre Hospitalier Universitaire de Liège - CHU > > Thérapie cellulaire
THYS, Marie ; Centre Hospitalier Universitaire de Liège - CHU > > Service des informations médico économiques (SIME)
Dardenne, Nadia ; Université de Liège - ULiège > Santé publique : de la Biostatistique à la Promotion de la Santé
Misset, Benoît ✱; Centre Hospitalier Universitaire de Liège - CHU > > Service des soins intensifs
BEGUIN, Yves ✱; Centre Hospitalier Universitaire de Liège - CHU > > Service d'hématologie clinique
✱ These authors have contributed equally to this work.
Language :
English
Title :
Bone Marrow-Derived Mesenchymal Stromal Cell Therapy in Severe COVID-19: Preliminary Results of a Phase I/II Clinical Trial
COVID-ICU Group on behalf of the REVA Network and the COVID-ICU Investigators. Clinical Characteristics and Day-90 Outcomes of 4244 Critically Ill Adults With COVID-19: A Prospective Cohort Study. Intensive Care Med (2021) 47(1):60–73. doi: 10.1007/s00134-020-06294-x
Hoffmann M Kleine-Weber H Schroeder S Krüger N Herrler T Erichsen S et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell (2020) 181(2):271–80.e8. doi: 10.1016/j.cell.2020.02.052
Osuchowski MF Winkler MS Skirecki T Cajander S Shankar-Hari M Lachmann G et al. The COVID-19 Puzzle: Deciphering Pathophysiology and Phenotypes of a New Disease Entity. Lancet Respir Med (2021) 9(6):622–42. doi: 10.1016/S2213-2600(21)00218-6
Grifoni A Weiskopf D Ramirez SI Mateus J Dan JM Moderbacher CR et al. Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans With COVID-19 Disease and Unexposed Individuals. Cell (2020) 181(7):1489–501.e15. doi: 10.1016/j.cell.2020.05.015
Liao M Liu Y Yuan J Wen Y Xu G Zhao J et al. Single-Cell Landscape of Bronchoalveolar Immune Cells in Patients With COVID-19. Nat Med (2020) 26(6):842–4. doi: 10.1038/s41591-020-0901-9
Robbiani DF Gaebler C Muecksch F Lorenzi JCC Wang Z Cho A et al. Convergent Antibody Responses to SARS-CoV-2 in Convalescent Individuals. Nature (2020) 584(7821):437–42. doi: 10.1038/s41586-020-2456-9
Laing AG Lorenc A Del Molino Del Barrio I Das A Fish M Monin L et al. A Dynamic COVID-19 Immune Signature Includes Associations With Poor Prognosis. Nat Med (2020) 26(10):1623–35. doi: 10.1038/s41591-020-1038-6
Bermejo-Martin JF González-Rivera M Almansa R Micheloud D Tedim AP Domínguez-Gil M et al. Viral RNA Load in Plasma is Associated With Critical Illness and a Dysregulated Host Response in COVID-19. Crit Care (2020) 24(1):691. doi: 10.1186/s13054-020-03398-0
De Biasi S Meschiari M Gibellini L Bellinazzi C Borella R Fidanza L et al. Marked T Cell Activation, Senescence, Exhaustion and Skewing Towards TH17 in Patients With COVID-19 Pneumonia. Nat Commun (2020) 11(1):3434. doi: 10.21203/rs.3.rs-23957/v1
Mathew D Giles JR Baxter AE Oldridge DA Greenplate AR Wu JE et al. Deep Immune Profiling of COVID-19 Patients Reveals Distinct Immunotypes With Therapeutic Implications. Science (2020) 369(6508):eabc8511. doi: 10.1126/science.abc8511
Grasselli G Tonetti T Protti A Langer T Girardis M Bellani G et al. Pathophysiology of COVID-19-Associated Acute Respiratory Distress Syndrome: A Multicentre Prospective Observational Study. Lancet Respir Med (2020) 8(12):1201–8. doi: 10.1016/S2213-2600(20)30370-2
Ader F Bouscambert-Duchamp M Hites M Peiffer-Smadja N Poissy J Belhadi D et al. Remdesivir Plus Standard of Care Versus Standard of Care Alone for the Treatment of Patients Admitted to Hospital With COVID-19 (DisCoVeRy): A Phase 3, Randomised, Controlled, Open-Label Trial. Lancet Infect Dis (2022) 22(2):209–21. doi: 10.1016/S1473-3099(21)00485-0
Pan H Peto R Henao-Restrepo AM Preziosi MP Sathiyamoorthy V Abdool Karim Q et al. Repurposed Antiviral Drugs for Covid-19 - Interim WHO Solidarity Trial Results. N Engl J Med (2021) 384(6):497–511. doi: 10.1056/NEJMoa2023184
RECOVERY Collaborative GroupHorby P Lim WS Emberson JR Mafham M Bell JL et al. Dexamethasone in Hospitalized Patients With Covid-19. N Engl J Med (2021) 384(8):693–704. doi: 10.1056/NEJMoa2021436
World Health Organization (WHO) Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group. Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19: A Meta-Analysis. JAMA (2021) 326(6):499–518. doi: 10.1001/jama.2021.11330
Ely EW Ramanan AV Kartman CE de Bono S Liao R Piruzeli MLB et al. Efficacy and Safety of Baricitinib Plus Standard of Care for the Treatment of Critically Ill Hospitalised Adults With COVID-19 on Invasive Mechanical Ventilation or Extracorporeal Membrane Oxygenation: An Exploratory, Randomised, Placebo-Controlled Trial. Lancet Respir Med (2022) 10(4):327–36. doi: 10.1016/S2213-2600(22)00006-6
Lambermont B Rousseau AF Seidel L Thys M Cavalleri J Delanaye P et al. Outcome Improvement Between the First Two Waves of the Coronavirus Disease 2019 Pandemic in a Single Tertiary-Care Hospital in Belgium. Crit Care Explor (2021) 3(5):e0438. doi: 10.1097/CCE.0000000000000438
Le Blanc K Mougiakakos D. Multipotent Mesenchymal Stromal Cells and the Innate Immune System. Nat Rev Immunol (2012) 12(5):383–96. doi: 10.1038/nri3209
Rohban R Pieber TR. Mesenchymal Stem and Progenitor Cells in Regeneration: Tissue Specificity and Regenerative Potential. Stem Cells Int (2017) 2017:5173732. doi: 10.1155/2017/5173732
Servais S Grégoire C Baron F Willems E Briquet A Baudoux E et al. Multipotent Mesenchymal Stromal Cell Therapy for Steroid-Refractory Acute Graft-Versus-Host Disease After Allogeneic Stem Cell Transplantation. Belgian J Hematol (2016) 7:229–35.
Grégoire C Lechanteur C Briquet A Baudoux E Baron F Louis E et al. Review Article: Mesenchymal Stromal Cell Therapy for Inflammatory Bowel Diseases. Aliment Pharmacol Ther (2017) 45(2):205–21. doi: 10.1111/apt.13864
Ren G Zhang L Zhao X Xu G Zhang Y Roberts AI et al. Mesenchymal Stem Cell-Mediated Immunosuppression Occurs via Concerted Action of Chemokines and Nitric Oxide. Cell Stem Cell (2008) 2(2):141–50. doi: 10.1016/j.stem.2007.11.014
Hung SC Pochampally RR Hsu SC Sanchez C Chen SC Spees J et al. Short-Term Exposure of Multipotent Stromal Cells to Low Oxygen Increases Their Expression of CX3CR1 and CXCR4 and Their Engraftment In Vivo. PloS One (2007) 2(5):e416. doi: 10.1371/journal.pone.0000416
Hung SC Pochampally RR Chen SC Hsu SC Prockop DJ. Angiogenic Effects of Human Multipotent Stromal Cell Conditioned Medium Activate the PI3K-Akt Pathway in Hypoxic Endothelial Cells to Inhibit Apoptosis, Increase Survival, and Stimulate Angiogenesis. Stem Cells (2007) 25(9):2363–70. doi: 10.1634/stemcells.2006-0686
Leng Z Zhu R Hou W Feng Y Yang Y Han Q et al. Transplantation of ACE2- Mesenchymal Stem Cells Improves the Outcome of Patients With COVID-19 Pneumonia. Aging Dis (2020) 11(2):216–28. doi: 10.14336/AD.2020.0228
Atluri S Manchikanti L Hirsch JA. Expanded Umbilical Cord Mesenchymal Stem Cells (UC-MSCs) as a Therapeutic Strategy in Managing Critically Ill COVID-19 Patients: The Case for Compassionate Use. Pain Phys (2020) 23(2):E71–83.
Lechanteur C Briquet A Giet O Delloye O Baudoux E Beguin Y. Clinical-Scale Expansion of Mesenchymal Stromal Cells: A Large Banking Experience. J Trans Med (2016) 14(1):145–. doi: 10.1186/s12967-016-0892-y
Lechanteur C Briquet A Bettonville V Baudoux E Beguin Y. MSC Manufacturing for Academic Clinical Trials: From a Clinical-Grade to a Full GMP-Compliant Process. Cells (2021) 10(6):1320. doi: 10.3390/cells10061320
WHO Working Group on the Clinical Characterisation and Management of COVID-19 infection. A Minimal Common Outcome Measure Set for COVID-19 Clinical Research. Lancet Infect Dis (2020) 20(8):e192–e7. doi: 10.1016/S1473-3099(20)30483-7
Lim ZJ Subramaniam A Ponnapa Reddy M Blecher G Kadam U Afroz A et al. Case Fatality Rates for Patients With COVID-19 Requiring Invasive Mechanical Ventilation. A Meta-Analysis. Am J Respir Crit Care Med (2021) 203(1):54–66. doi: 10.1164/rccm.202006-2405OC
Aranda J Oriol I Martín M Feria L Vázquez N Rhyman N et al. Long-Term Impact of COVID-19 Associated Acute Respiratory Distress Syndrome. J Infect (2021) 83(5):581–8. doi: 10.1016/j.jinf.2021.08.018
Rousseau AF Minguet P Colson C Kellens I Chaabane S Delanaye P et al. Post-Intensive Care Syndrome After a Critical COVID-19: Cohort Study From a Belgian Follow-Up Clinic. Ann Intensive Care (2021) 11(1):118. doi: 10.1186/s13613-021-00910-9
Boucher PE Taplin J Clement F. The Cost of ARDS: A Systematic Review. Chest (2022) 161(3):684–96. doi: 10.1016/j.chest.2021.08.057
Galleu A Riffo-Vasquez Y Trento C Lomas C Dolcetti L Cheung TS et al. Apoptosis in Mesenchymal Stromal Cells Induces In Vivo Recipient-Mediated Immunomodulation. Sci Trans Med (2017) 9(416):eaam7828–eaam. doi: 10.1126/scitranslmed.aam7828
Lee RH Pulin AA Seo MJ Kota DJ Ylostalo J Larson BL et al. Intravenous hMSCs Improve Myocardial Infarction in Mice Because Cells Embolized in Lung are Activated to Secrete the Anti-Inflammatory Protein TSG-6. Cell Stem Cell (2009) 5(1):54–63. doi: 10.1016/j.stem.2009.05.003
Lopes-Pacheco M Robba C Rocco PRM Pelosi P. Current Understanding of the Therapeutic Benefits of Mesenchymal Stem Cells in Acute Respiratory Distress Syndrome. Cell Biol Toxicol (2020) 36(1):83–102. doi: 10.1007/s10565-019-09493-5
Zheng G Huang L Tong H Shu Q Hu Y Ge M et al. Treatment of Acute Respiratory Distress Syndrome With Allogeneic Adipose-Derived Mesenchymal Stem Cells: A Randomized, Placebo-Controlled Pilot Study. Respir Res (2014) 15(1):39. doi: 10.1186/1465-9921-15-39
Wilson JG Liu KD Zhuo H Caballero L McMillan M Fang X et al. Mesenchymal Stem (Stromal) Cells for Treatment of ARDS: A Phase 1 Clinical Trial. Lancet Respir Med (2015) 3(1):24–32. doi: 10.1016/S2213-2600(14)70291-7
Matthay MA Calfee CS Zhuo H Thompson BT Wilson JG Levitt JE et al. Treatment With Allogeneic Mesenchymal Stromal Cells for Moderate to Severe Acute Respiratory Distress Syndrome (START Study): A Randomised Phase 2a Safety Trial. Lancet Respir Med (2019) 7(2):154–62. doi: 10.1016/S2213-2600(18)30418-1
Ringdén O Moll G Gustafsson B Sadeghi B. Mesenchymal Stromal Cells for Enhancing Hematopoietic Engraftment and Treatment of Graft-Versus-Host Disease, Hemorrhages and Acute Respiratory Distress Syndrome. Front Immunol (2022) 13:839844. doi: 10.3389/fimmu.2022.839844
Meng F Xu R Wang S Xu Z Zhang C Li Y et al. Human Umbilical Cord-Derived Mesenchymal Stem Cell Therapy in Patients With COVID-19: A Phase 1 Clinical Trial. Signal Transduct Target Ther (2020) 5(1):172. doi: 10.1038/s41392-020-00286-5
Guo Z Chen Y Luo X He X Zhang Y Wang J. Administration of Umbilical Cord Mesenchymal Stem Cells in Patients With Severe COVID-19 Pneumonia. Crit Care (2020) 24(1):420. doi: 10.1186/s13054-020-03142-8
Xu X Jiang W Chen L Xu Z Zhang Q Zhu M et al. Evaluation of the Safety and Efficacy of Using Human Menstrual Blood-Derived Mesenchymal Stromal Cells in Treating Severe and Critically Ill COVID-19 Patients: An Exploratory Clinical Trial. Clin Transl Med (2021) 11(2):e297. doi: 10.1002/ctm2.297
Hashemian SR Aliannejad R Zarrabi M Soleimani M Vosough M Hosseini SE et al. Mesenchymal Stem Cells Derived From Perinatal Tissues for Treatment of Critically Ill COVID-19-Induced ARDS Patients: A Case Series. Stem Cell Res Ther (2021) 12(1):91. doi: 10.1186/s13287-021-02165-4
Iglesias M Butrón P Torre-Villalvazo I Torre-Anaya EA Sierra-Madero J Rodriguez-Andoney JJ et al. Mesenchymal Stem Cells for the Compassionate Treatment of Severe Acute Respiratory Distress Syndrome Due to COVID 19. Aging Dis (2021) 12(2):360–70. doi: 10.14336/AD.2020.1218
Häberle H Magunia H Lang P Gloeckner H Körner A Koeppen M et al. Mesenchymal Stem Cell Therapy for Severe COVID-19 ARDS. J Intensive Care Med (2021) 36(6):681–8. doi: 10.1177/0885066621997365.
Ercelen N Pekkoc-Uyanik KC Alpaydin N Gulay GR Simsek M. Clinical Experience on Umbilical Cord Mesenchymal Stem Cell Treatment in 210 Severe and Critical COVID-19 Cases in Turkey. Stem Cell Rev Rep (2021) 17(5):1917–25. doi: 10.1007/s12015-021-10214-x
Lanzoni G Linetsky E Correa D Messinger Cayetano S Alvarez RA Kouroupis D et al. Umbilical Cord Mesenchymal Stem Cells for COVID-19 Acute Respiratory Distress Syndrome: A Double-Blind, Phase 1/2a, Randomized Controlled Trial. Stem Cells Transl Med (2021). doi: 10.1002/sctm.20-0472
Monsel A Hauw-Berlemont C Mebarki M Heming N Mayaux J Nguekap Tchoumba O et al. Treatment of COVID-19-Associated ARDS With Mesenchymal Stromal Cells: A Multicenter Randomized Double-Blind Trial. Crit Care (2022) 26(1):48. doi: 10.1186/s13054-022-03930-4
Shi L Huang H Lu X Yan X Jiang X Xu R et al. Effect of Human Umbilical Cord-Derived Mesenchymal Stem Cells on Lung Damage in Severe COVID-19 Patients: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial. Signal Transduct Target Ther (2021) 6(1):58. doi: 10.1038/s41392-021-00488-5
Dilogo IH Aditianingsih D Sugiarto A Burhan E Damayanti T Sitompul PA et al. Umbilical Cord Mesenchymal Stromal Cells as Critical COVID-19 Adjuvant Therapy: A Randomized Controlled Trial. Stem Cells Transl Med (2021) 10(9):1279–87. doi: 10.1002/sctm.21-0046
Shu L Niu C Li R Huang T Wang Y Huang M et al. Treatment of Severe COVID-19 With Human Umbilical Cord Mesenchymal Stem Cells. Stem Cell Res Ther (2020) 11(1):361. doi: 10.1186/s13287-020-01875-5
Bikdeli B Madhavan MV Jimenez D Chuich T Dreyfus I Driggin E et al. COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up: JACC State-Of-the-Art Review. J Am Coll Cardiol (2020) 75(23):2950–73. doi: 10.1016/j.jacc.2020.04.031
Grégoire C Ritacco C Hannon M Seidel L Delens L Belle L et al. Comparison of Mesenchymal Stromal Cells From Different Origins for the Treatment of Graft-Vs.-Host-Disease in a Humanized Mouse Model. Front Immunol (2019) 10:619. doi: 10.3389/fimmu.2019.00619
Moll G Ignatowicz L Catar R Luecht C Sadeghi B Hamad O et al. Different Procoagulant Activity of Therapeutic Mesenchymal Stromal Cells Derived From Bone Marrow and Placental Decidua. Stem Cells Dev (2015) 24(19):2269–79. doi: 10.1089/scd.2015.0120
Moll G Drzeniek N Kamhieh-Milz J Geissler S Volk H-D Reinke P. MSC Therapies for COVID-19: Importance of Patient Coagulopathy, Thromboprophylaxis, Cell Product Quality and Mode of Delivery for Treatment Safety and Efficacy. Front Immunol (2020) 11:1091. doi: 10.3389/fimmu.2020.01091.
Wiersinga WJ Rhodes A Cheng AC Peacock SJ Prescott HC. Pathophysiology, Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19): A Review. JAMA (2020) 324(8):782–93. doi: 10.1001/jama.2020.12839
Moll G Ankrum JA Olson SD Nolta JA. Improved MSC Minimal Criteria to Maximize Patient Safety: A Call to Embrace Tissue Factor and Hemocompatibility Assessment of MSC Products. Stem Cells Trans Med (2022) 11(1):2–13. doi: 10.1093/stcltm/szab005
Pires AO Mendes-Pinheiro B Teixeira FG Anjo SI Ribeiro-Samy S Gomes ED et al. Unveiling the Differences of Secretome of Human Bone Marrow Mesenchymal Stem Cells, Adipose Tissue-Derived Stem Cells, and Human Umbilical Cord Perivascular Cells: A Proteomic Analysis. Stem Cells Dev (2016) 25(14):1073–83. doi: 10.1089/scd.2016.0048
Cottle C AP P Lipat A Turner-Lyles C Nguyen J Moll G et al. Impact of Cryopreservation and Freeze-Thawing on Therapeutic Properties of Mesenchymal Stromal/Stem Cells and Other Common Cellular Therapeutics. Curr Stem Cell Rep (2022) 8(2):72–92. doi: 10.1007/s40778-022-00212-1
